<?xml version="1.0" encoding="UTF-8"?>
<p id="Par104">We conclude that CD34+ cell function improves post saxagliptin therapy compared to a matched placebo in an early onset type 2 diabetes population that did not have any known cardiovascular disease or complications. We believe CD34+ cells can act as a valuable biomarker for assessment of endothelial function, in a setting of diabetes and can help provide valuable information using cellular data, to support or refute findings from other cardiovascular outcome trials in diabetes [
 <xref ref-type="bibr" rid="CR44">44</xref>, 
 <xref ref-type="bibr" rid="CR58">58</xref>â€“
 <xref ref-type="bibr" rid="CR60">60</xref>].
</p>
